Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas
暂无分享,去创建一个
S. Solomon | M. Pfeffer | J. McMurray | A. Zauber | M. Bertagnolli | B. Levin | J. Wittes | E. Hawk | N. Arber | P. Finn | C. Eagle | R. Fowler | M. Lechuga
[1] Y. Cen. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas". , 2007, Circulation.
[2] S. Solomon,et al. Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.
[3] S. Solomon,et al. Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.
[4] M. Bertagnolli,et al. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. , 2006, Cancer research.
[5] Garret A FitzGerald,et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.
[6] F. Messerli,et al. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? , 2005, The American journal of cardiology.
[7] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[8] Robert Riddell,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[9] Andreas Hoeft,et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.
[10] Thomas Brabant,et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.
[11] J. Avorn,et al. Relationship Between COX-2 Specific Inhibitors and Hypertension , 2004, Hypertension.
[12] G. Bakris,et al. Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics , 2004, Hypertension.
[13] W. White,et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.
[14] K. Brune,et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet , 2002, Clinical pharmacology and therapeutics.
[15] W. White,et al. Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors , 2002, Hypertension.
[16] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[17] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[18] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] P. Loehrer. Celecoxib for the Prevention of Colorectal Adenomatous Polyps , 2008 .
[20] W. Frishman. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2006 .
[21] Ken W. Woodhouse,et al. The Clinical Perspective , 1994 .